Amarin Corporation plc

NASDAQ:AMRN

Biotechnology

Healthcare
$11.26 +1.84%

+$0.29 today

Market cap
$232.89M
Beta
0.82
P/E (TTM)
-9.9
EPS (TTM)
-$1.62
52W Low $12.30High $20.90

Volume 0.09M

Average 0.07M

AMRN Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Amarin Corporation plcNASDAQ: AMRN

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income dips below year-ago levels

Q1 FY2026 net income of $10.51M (cash outflow) fell 33.0% year over year, behind the +106.0% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at -28.4% a year.

Context

  • Net income amounted to 18.2% of revenue in FY2025, down 17.8 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of -$23.4M (-39.7%) for the fiscal year ending Dec 2026, a step up from the -52.8% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$10.51M-128.0% QoQ
Last fiscal yearDec 2025
-$38.8M-52.8% YoY
LTMMar 2026
$5.23M+106.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-33.0%-98.5%-65.5 pp
1 year-52.8%-39.7%+13.1 pp
3-year CAGR-28.4%-23.8%+4.6 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(38.8M) USD
Year-over-year change
+52.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How AMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +106.0% is the highest of 10, against a peer median of +29.8%.
  • Net income amounts to 2.4% of revenue for AMRN, versus a peer median of 9368.4%.
AMRN Competitors
Net Income for AMRN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LYELLyell Immunopharma, Inc.LTM Mar 2026$246.41M USD-26.3%+14.4%794858.1%
DBVTDBV Technologies S.A.LTM Mar 2026$167.47M USD+47.3%+15.1%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$166.01M USD+74.3%+67.3%—
SLNSilence Therapeutics plcLTM Mar 2026$145.44M USD—+20.7%15782.6%
ENGNenGene Holdings Inc.LTM Apr 2026$126.85M USD+58.8%+68.6%—
KRROKorro Bio, Inc.LTM Mar 2026$113.5M USD+29.8%+26.4%2954.1%
ALTAltimmune, Inc.LTM Mar 2026$91.08M USD+0.9%+1.3%253002.8%
ANROAlto Neuroscience, Inc.LTM Mar 2026$74.31M USD+17.6%+31.7%—
ACIUAC Immune S.A.LTM Dec 2025CHF 70.34M CHF+38.1%-1.7%1968.6%
CLLSCellectis S.A.LTM Mar 2026$67.27M USD+11.1%-11.8%98.8%
AMRNAmarin Corporation plcLTM Mar 2026$5.23M USD+106.0%-28.4%2.4%
Peer median (excluding AMRN) —+29.8%+17.9%9368.4%

Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income7.73M(105.74M)(59.34M)(82.18M)(38.8M)
Depreciation & Amortization2.86M3.09M2.98M3.01M3.03M
Deferred Income Tax00000
Stock-Based Compensation00017.71M13.94M
Change in Working Capital(115.98M)(104.01M)51.27M36.17M32.28M
Accounts Receivables(8.34M)32.98M(2.33M)11.22M(3.83M)
Inventory(167.05M)(36.4M)56.34M105.44M34.96M
Accounts Payables51.51M(102.67M)(164.64K)(77.02M)14.54M
Other Working Capital7.9M2.07M(2.56M)(3.5M)(13.39M)
Other Non-Cash Items38.86M26.67M12M(5.73M)(3.71M)
Operating Cash Flow(66.53M)(179.98M)6.91M(31.03M)6.74M
Capital Expenditures2(2)(24.1K)20
Acquisitions (Net)4K0000
Purchases of Investments(290.16M)(81.58M)(215.93M)(278.78M)(200.94M)
Sales of Investments394.25M257.36M190.84M232.8M209.79M
Other Investing Activities00000
Investing Cash Flow104.09M175.18M(25.62M)(45.98M)8.85M
Debt Repayment00000
Common Stock Issued4.57M664.59K2.22M131.06K140.33K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(9.64M)(1.04M)(1.99M)(1.57M)(2.18M)
Financing Cash Flow(5.07M)(378.77K)230.89K(1.44M)(2.04M)
Effect of Forex Changes3.87K(3.2K)71.37K33.01K(31.6K)
Net Change in Cash32.49M(5.18M)(18.41M)(78.44M)13.52M
Free Cash Flow(66.53M)(179.98M)6.88M(31.02M)6.74M

Amarin Corporation plc

NASDAQ:AMRN

Intrinsic Alpha fair value

Locked

Current Price

$11.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.